Showing 81-90 of 7273 results for "".
Hilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.DermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshIn the Pipeline: New Approaches to Vitiligo, Congenital Ichthyosis, and More
https://practicaldermatology.com/topics/pigmentary-disorders/in-the-pipeline-new-approaches-to-vitiligo-congenital-ichthyosis-and-more/23714/Inflammatory diseases with few or no specific treatments may soon have approved interventions.Tips for Filling the Jaw, Chin, and Mid-face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-for-filling-the-jaw-chin-and-mid-face/23598/CSF faculty members share pearls for injecting new fillers.Managing Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.Scientifically Speaking: Optimized Approaches to AK Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-optimized-approaches-to-ak-management/19912/What's new in AK therapy? From a new, first-in-class molecule to updated approaches with long-standing treatments, the management of actinic keratosis continues to evolve. Scientifically Speaking host Joel L. Cohen, MD speaks with Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD about theILUMYA SUPPORT™ patient access for commercial and Medicare Part B patients
https://practicaldermatology.com/topics/psoriasis/ilumya-support-patient-access-for-commercial-and-medicare-part-b-patients/19860/ILUMYA SUPPORT™ offers comprehensive programs and services to help patients start and stay on therapy with ILUMYA™. Learn about the three main patient access programs offered by ILUMYA SUPPORT™: the Early Access Program, the Co-pay Program, and the Patient Assistance Program. ILUMYA™ is reimbursed uProviding Quality Customer Service Behind the Mask
https://practicaldermatology.com/topics/practice-management/providing-quality-customer-service-behind-the-mask/23400/Eight ways to make a good impression and provide excellent customer service.The Importance of a Broad Social Media Presence in Dermatology
https://practicaldermatology.com/topics/practice-management/the-importance-of-a-broad-social-media-presence-in-dermatology/23399/Meet your current and potential patients on the social media platforms they prefer.